BIOFILCHEM — Biofil Chemicals and Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.25bn
- IN₹1.24bn
- IN₹400.35m
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 297 | 358 | 224 | 300 | 400 |
Cost of Revenue | |||||
Gross Profit | 43.8 | 33.2 | 29.2 | 26.1 | 25.3 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 283 | 346 | 215 | 293 | 396 |
Operating Profit | 14.1 | 11.9 | 9.05 | 7.42 | 4.17 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14.6 | 19.2 | 10.1 | 7.93 | 8.65 |
Provision for Income Taxes | |||||
Net Income After Taxes | 12.1 | 12.4 | 6.98 | 5.6 | 7.09 |
Net Income Before Extraordinary Items | |||||
Net Income | 12.1 | 12.4 | 6.98 | 5.6 | 7.09 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 12.1 | 12.4 | 6.98 | 5.6 | 7.09 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.742 | 0.763 | 0.429 | 0.344 | 0.436 |
Dividends per Share |